Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KA 2237

Drug Profile

KA 2237

Alternative Names: CVL-237; KA2237; PI3 Kinase p110β/δ inhibitor

Latest Information Update: 12 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Karus Therapeutics
  • Developer Karus Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I B-cell lymphoma
  • Preclinical Inflammation

Most Recent Events

  • 05 Mar 2024 Convalife plans a phase II/III trial for Immunodeficiency disorders in China (PO, Tablet) in March 2024 (NCT06293716)
  • 25 Dec 2023 Convalife plans a phase II trial for Solid tumours (Late-stage disease) in China (NCT06183736)
  • 29 Mar 2023 KA 2237 is still in phase I development for B-cell lyphoma in the US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top